|
1.1 BIOLOGIE - GÉNOME
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
|
|
|
|
4.15 DÉP., DIAG. & PRONO. - IMAGERIE
|
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
5.10 TRAITEMENTS - ESSAIS
|
|
|
|
5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE
|
|
|
|
5.12.6 IMMUNOTHÉRAPIES - AMM
|
|
|
|
5.17 TRAITEMENTS - RADIOTHÉRAPIE
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
Do the Costs of Cancer Drugs Receive Enough Attention? [Wiley]
|
|
|
|
|
|
Among the 43 submissions that were evaluated by pCODR, the gain in QALYs in most submissions was small, and in almost two-thirds (65 percent) of cases, the submitter’s best estimate of cost-effectiveness of the drug was in excess of $100,000 per QALY. More than half (56 percent) of submissions did not include original data on health-related quality of life, with most relying instead on evidence from previous studies.
|
|
|
|
|
|
|
5.6 ESMO
|
|
|
|
6. LUTTE CONTRE LES CANCERS
|
|
|
|
|
6.11 PATIENTS
|
|
|
Is Everyone Doing Chemo Without Me? [NY Times]
|
|
|
|
|
|
The TAILORx study, the largest ever breast cancer treatment trial based on over 10,000 patients’ recurrence scores, had just been published, showing that 70 percent of women with my type of early stage breast cancer could avoid chemotherapy. My score was right on the cusp.
|
|
|
|
|
|